C-EQAXDorian Therapeutics
cell rejuvenation, cellular resilience
reprogrammingepigenetic reprogramming
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EQAX
C-EQAXC-EQAXcell rejuvenation, cellular resilience
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Dorian Therapeutics states that aging is a common risk factor behind most diseases in the developed world and argues that age-related decline is driven by reduced stem cell activity, diminished regenerative capacity, and the accumulation of senescent cells that damage tissues. The company presents senoblockers as a new therapeutic class that acts on epigenetic regulators to reverse these processes, restoring youthfulness and regeneration in cells and tissues.
SourceDorian Therapeutics states that aging should be fought by blocking cellular senescence, and that doing so can improve medical conditions. The snapshot presents this as the company’s core belief and framing for its work.
SourceDorian Therapeutics states that aging is the shared risk factor behind most diseases in the developed world and that treating the biology of aging can address major unmet medical needs. The company presents senoblockers as a new therapeutic class that can rejuvenate cells and tissues by reversing age-related stem cell decline and counteracting the harmful buildup of senescent cells.
SourceDorian Therapeutics states that aging is the common risk factor behind many major diseases and that addressing the biology of aging can meet these unmet medical needs. The company believes senoblockers, based on Stanford-developed patented technology, can rejuvenate cells and tissues by reversing age-related stem cell decline and counteracting the harmful accumulation of senescent cells.
Source